Lincoln Capital Corp’s GSK GSK Stock Holding History

Lincoln Capital Corp’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,550	Closed	-$213K	–	92
2025 Q2	$213K	Buy	+5,550	New	+$212K	0.08%	85

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lincoln Capital Corp's GSK Position: Q3 2025 in Review

Lincoln Capital Corp sold out of GSK (GSK) in Q3 2025, closing a stake of 5,550 shares — an estimated $213K sold.

Lincoln Capital Corp first reported a position in GSK in Q2 2025 and held it in 1 quarter. The position peaked at $213K in Q2 2025. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Lincoln Capital Corp reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
Lincoln Capital Corp sold 5,550 GSK shares in Q3 2025, an estimated $213K.
Lincoln Capital Corp first reported a position in GSK in Q2 2025 and held it in 1 quarter.
Lincoln Capital Corp's GSK position peaked at $213K in Q2 2025.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Lincoln Capital Corp's 13F filing for Q3 2025, filed 16 Oct 2025.